Navigation Links
New DrugDev Educational Webinar Shows Pharma How to Put the “Informed" Back Into Patient Consent for Global Clinical Studies with Groundbreaking Mobile Solution
Date:12/12/2016

Sponsors and CROs who cling to outmoded paper consent processes take a tremendous risk: 10-15% of audit findings relate to informed consent.

Join DrugDev for a live webinar December 14, 11am-12pm EST as DrugDev eConsent experts Eric Delente and Susan Brink DrPH review the current state of eConsent (electronic informed consent), offer actionable advice, and give a brief demo of pharma's gold standard eConsent solution which is part of the unified DrugDev technology platform. (DrugDev acquired SecureConsent, the company behind DrugDev’s eConsent technology, last month. You can read the news release here.)

Webinar: DrugDev eConsent - Putting "Informed" Back into Patient Consent
Date: December 14, 2016
Time: 11:00am-12:00pm EST
Click to register.
This webinar is complimentary

Draft FDA guidance and patient advocacy groups are driving adoption of eConsent (electronic informed consent) because it makes the consenting process more efficient and effective for staff, sponsors, monitors – and most important, patients. eConsent experts Eric Delente and Susan Brink DrPH will show and tell attendees how this revolutionary technology helps pharma sponsors and CROs:

  • Ensure consistent messaging for all patients
  • Solve common challenges such as multiple languages and version control
  • Improve patient retention through increased comprehension and satisfaction
  • Manage real-time biosample consent
  • Comply with global requirements

DrugDev’s fully validated eConsent solution was further developed in DrugDev’s Innovation Lab under the guidance of Executive Chair Hugo Stephenson MD. It gives sites and patients the ability to use attractive technology on virtually any mobile device including BYOD. It focuses patient attention with features including educational videos, audio narration and easy-to-understand documents and a glossary.

About the Speakers
Eric Delente, President, DrugDev Patient Solutions – Eric is recognized throughout the pharma industry for his thorough understanding of educational technology and his passion to improve the clinical trial process by better informing patients. He has been designing, developing, hosting and maintaining award-winning education portals for healthcare and science organizations for more than 20 years, most recently at Secure Consent (acquired by DrugDev). eConsent groundbreaking product lines created by Eric are the result of years of deep research, regulatory alignment and testing. These systems are being deployed successfully in dozens of studies worldwide.

Susan Brink DrPH, Strategic Advisor, DrugDev Patient Solutions – Susan is an expert in self-care and decision-making for patients, continuing education for health care providers, and health education for children. She teamed with Eric Delente to develop online informed consent for clinical trials. As the PI for the Phase I and II SBIRs Susan led the team in conducting formative research, determining patient and clinician needs, formulating intervention and evaluating the use of the resulting eConsent with patients and lay persons. Susan has served as faculty at the Pediatrics Dept. at the University of Texas Medical Branch in Galveston TX, and at the University of Texas School of Public Health.

For more on how DrugDev eConsent is revolutionizing the informed consent process read what top industry editors are saying about the DrugDev Site eConsent solution in the Philadelphia Business Journal, Clinical Leader, Clinical Informatics News, and CenterWatch.

About DrugDev
DrugDev’s unified clinical suite enables sponsors, CROs and sites to do more trials through industry-wide collaboration, standardization and a beautiful technology experience. Featuring solutions for global site payments, site identification and activation, workflow optimization, learning management, and site and patient engagement, DrugDev helps companies transform the quality and efficiency of clinical trials from startup through closeout. The company also powers the revolutionary TransCelerate Investigator Registry and Investigator Databank collaborations with the universal identifier known as the DrugDev Golden Number. Learn more at http://www.drugdev.com.

Read the full story at http://www.prweb.com/releases/2016/12/prweb13917954.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related medicine news :

1. Leading Clinical Trial Technology Innovator DrugDev Achieves EU-U.S. Privacy Shield Certification
2. DrugDev Adds the Definitive eConsent Mobile Solution to Its Unified Clinical Operations Suite with Acquisition of Pioneering Market Leader SecureConsent
3. Learn How DrugDev has Become the Fastest Growing Clinical Trials Technology Company by Transforming Site Selection, Activation, Payments, and Engagement at New Webinar
4. DrugDev Celebrates 2016 Clinical Trials Day with the Unveiling of its New Site Perspectives Video Wall
5. DrugDev Hosts New Educational Webinar: Conquer the Challenges of Investigator Payments in Global Clinical Trials
6. DrugDev President and CEO Ibraheem “Ibs” Mahmood Named to The Medicine Maker International Power 100, Honored as Tech Disruptor by the Philadelphia Business Journal
7. DrugDev to Speak on Clinical Trial Industry Standardization, Collaboration and Technology Advances at Executive Summit on Site Strategies and ACRP Meeting & Expo
8. Clinical Trial Sponsors and CROs Standardize on the DrugDev Golden Number as the Universal Identifier for Global Investigators and Sites
9. DrugDev Webinar Offers Live Demo of New SaaS Version of Site Activation Technology to Decrease Clinical Trial Startup Time from Months to Weeks
10. DrugDev and Exostar Collaborate to Streamline and Secure Clinical Trial Process by Linking Exostar Identity Credential with the DrugDev Golden Number
11. DrugDev Launches Clinical Site Activation SaaS Technology as Key Part of Its Unified Platform to Reduce the Time of Startup from Months to Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care ... MD Now’s 28th facility overall and marks the urgent care center's eighth location in ... North of The Falls shopping mall. The new clinic offers a wide array of ...
(Date:6/23/2017)... ... ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an upcoming episode ... Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for more info. ... 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in science and ...
(Date:6/23/2017)... Chicago, IL (PRWEB) , ... June 23, 2017 ... ... insurance management assistance and financial planning services to communities in the greater Chicago ... Children’s Association to offer assistance to underprivileged youth in Chicago. , Founded in ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... is pleased to welcome Whipple & Company as its newest Partner Firm. Headquartered ... of balancing their clients’ risk while tailoring optimized benefit packages that strengthen the ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: